CH622501A5 - - Google Patents
Download PDFInfo
- Publication number
- CH622501A5 CH622501A5 CH334376A CH334376A CH622501A5 CH 622501 A5 CH622501 A5 CH 622501A5 CH 334376 A CH334376 A CH 334376A CH 334376 A CH334376 A CH 334376A CH 622501 A5 CH622501 A5 CH 622501A5
- Authority
- CH
- Switzerland
- Prior art keywords
- oxime
- salts
- pharmaceutically acceptable
- preparation
- aminoethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 37
- -1 ethoxy, methoxymethyl Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 150000007513 acids Chemical class 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 241000251730 Chondrichthyes Species 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 2
- 125000003544 oxime group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 150000002923 oximes Chemical class 0.000 claims 7
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical class ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims 1
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- OUASXEXUMGYCHN-UHFFFAOYSA-N 1-(4-bromophenyl)-5-(2-methoxyethoxy)pentan-1-one Chemical compound COCCOCCCCC(=O)C1=CC=C(Br)C=C1 OUASXEXUMGYCHN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
- ZNTQOKSIKTZIDA-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-ethoxypentan-1-one Chemical compound CCOCCCCC(=O)C1=CC=C(Cl)C=C1 ZNTQOKSIKTZIDA-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- KDFBGNBTTMPNIG-UHFFFAOYSA-N hydron;2-(1h-indol-3-yl)ethanamine;chloride Chemical compound Cl.C1=CC=C2C(CCN)=CNC2=C1 KDFBGNBTTMPNIG-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- VAWHTWXBNQFBAJ-UHFFFAOYSA-N o-(2-aminoethyl)hydroxylamine;dihydrochloride Chemical compound Cl.Cl.NCCON VAWHTWXBNQFBAJ-UHFFFAOYSA-N 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229960005333 tetrabenazine Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HMVSSTKMGGDQHU-UHFFFAOYSA-N 1-(4-bromophenyl)-5-methoxypentan-1-one Chemical compound COCCCCC(=O)C1=CC=C(Br)C=C1 HMVSSTKMGGDQHU-UHFFFAOYSA-N 0.000 description 1
- MTOBQCCPWAQJME-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2-methoxyethoxy)pentan-1-one Chemical compound COCCOCCCCC(=O)C1=CC=C(Cl)C=C1 MTOBQCCPWAQJME-UHFFFAOYSA-N 0.000 description 1
- JALPGJKSTDFZGS-UHFFFAOYSA-N 1-(4-chlorophenyl)-6-ethoxyhexan-1-one Chemical compound CCOCCCCCC(=O)C1=CC=C(Cl)C=C1 JALPGJKSTDFZGS-UHFFFAOYSA-N 0.000 description 1
- CWWSYIUBTJBWJP-UHFFFAOYSA-N 1-(4-chlorophenyl)-6-methoxyhexan-1-one Chemical compound COCCCCCC(=O)C1=CC=C(Cl)C=C1 CWWSYIUBTJBWJP-UHFFFAOYSA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- CWRLGOQGDFIMTM-UHFFFAOYSA-N 6-(4-bromophenyl)-6-oxohexanenitrile Chemical compound BrC1=CC=C(C(=O)CCCCC#N)C=C1 CWRLGOQGDFIMTM-UHFFFAOYSA-N 0.000 description 1
- MKJIEFSOBYUXJB-UHFFFAOYSA-N 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2CC(CC(C)C)C(=O)CC2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- XWTLTCQJBSZUDZ-UHFFFAOYSA-N ClC(CCC(=O)C1=CC=CC=C1)CCC#N Chemical compound ClC(CCC(=O)C1=CC=CC=C1)CCC#N XWTLTCQJBSZUDZ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940077481 dl- 5-hydroxytryptophan Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- UJTMLNARSPORHR-UHFFFAOYSA-N oc2h5 Chemical compound C=C=[O+] UJTMLNARSPORHR-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XKGLSKVNOSHTAD-UHFFFAOYSA-N valerophenone Chemical compound CCCCC(=O)C1=CC=CC=C1 XKGLSKVNOSHTAD-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
- C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/63—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton
- C07C255/64—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7503312A NL7503312A (nl) | 1975-03-20 | 1975-03-20 | Verbindingen met antidepressieve werking. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH622501A5 true CH622501A5 (sr) | 1981-04-15 |
Family
ID=19823426
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH334376A CH622501A5 (sr) | 1975-03-20 | 1976-03-17 | |
| CH32081A CH628617A5 (de) | 1975-03-20 | 1981-01-19 | Verfahren zur herstellung neuer verbindungen mit antidepressiver wirkung. |
| CH31981A CH630895A5 (de) | 1975-03-20 | 1981-01-19 | Verfahren zur herstellung neuer oximaetherverbindungen. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH32081A CH628617A5 (de) | 1975-03-20 | 1981-01-19 | Verfahren zur herstellung neuer verbindungen mit antidepressiver wirkung. |
| CH31981A CH630895A5 (de) | 1975-03-20 | 1981-01-19 | Verfahren zur herstellung neuer oximaetherverbindungen. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4086361A (sr) |
| JP (1) | JPS6055505B2 (sr) |
| AR (2) | AR211118A1 (sr) |
| AT (1) | AT340896B (sr) |
| AU (1) | AU505356B2 (sr) |
| BE (1) | BE839746A (sr) |
| CA (1) | CA1074813A (sr) |
| CH (3) | CH622501A5 (sr) |
| DD (1) | DD125686A5 (sr) |
| DE (1) | DE2609437A1 (sr) |
| DK (1) | DK143844C (sr) |
| ES (1) | ES446188A1 (sr) |
| FI (1) | FI62063C (sr) |
| FR (1) | FR2304334A1 (sr) |
| GB (1) | GB1531041A (sr) |
| GR (1) | GR59914B (sr) |
| HU (1) | HU171028B (sr) |
| IE (1) | IE43706B1 (sr) |
| IL (1) | IL49235A (sr) |
| IT (1) | IT1063061B (sr) |
| NL (1) | NL7503312A (sr) |
| PL (3) | PL100619B1 (sr) |
| SE (1) | SE425389B (sr) |
| SU (3) | SU668595A3 (sr) |
| YU (1) | YU70176A (sr) |
| ZA (1) | ZA761404B (sr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3692835A (en) * | 1967-04-05 | 1972-09-19 | Jan Van Dijk | Pharmacologically active amino-ethyl oximes |
| JPH058165Y2 (sr) * | 1985-08-30 | 1993-03-02 | ||
| US4844908A (en) * | 1986-11-27 | 1989-07-04 | Duphar International Research B.V. | Method of preparing tablets with clovoxamine fumarate and tablets thus prepared |
| FR2639942B1 (fr) * | 1988-12-02 | 1991-03-29 | Sanofi Sa | Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant |
| EP1925610A1 (de) * | 2006-11-24 | 2008-05-28 | Bayer CropScience AG | Verfahren zur Herstellung von 2-Aminooxyethanol |
| DK3544420T3 (da) | 2016-11-24 | 2022-09-05 | Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag | Anvendelse af sammensætninger til organ-/vævskonservering |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3692835A (en) * | 1967-04-05 | 1972-09-19 | Jan Van Dijk | Pharmacologically active amino-ethyl oximes |
-
1975
- 1975-03-20 NL NL7503312A patent/NL7503312A/xx not_active Application Discontinuation
-
1976
- 1976-03-06 DE DE19762609437 patent/DE2609437A1/de active Granted
- 1976-03-08 ZA ZA761404A patent/ZA761404B/xx unknown
- 1976-03-15 AR AR262561A patent/AR211118A1/es active
- 1976-03-17 FI FI760695A patent/FI62063C/fi not_active IP Right Cessation
- 1976-03-17 AT AT195576A patent/AT340896B/de not_active IP Right Cessation
- 1976-03-17 IT IT21323/76A patent/IT1063061B/it active
- 1976-03-17 PL PL1976188004A patent/PL100619B1/pl unknown
- 1976-03-17 DK DK116076A patent/DK143844C/da not_active IP Right Cessation
- 1976-03-17 PL PL1976199553A patent/PL100616B1/xx unknown
- 1976-03-17 HU HU76PI00000511A patent/HU171028B/hu not_active IP Right Cessation
- 1976-03-17 GR GR50335A patent/GR59914B/el unknown
- 1976-03-17 IL IL49235A patent/IL49235A/xx unknown
- 1976-03-17 PL PL1976199552A patent/PL101949B1/pl unknown
- 1976-03-17 CA CA248,107A patent/CA1074813A/en not_active Expired
- 1976-03-17 SE SE7603340A patent/SE425389B/xx not_active IP Right Cessation
- 1976-03-17 GB GB10701/76A patent/GB1531041A/en not_active Expired
- 1976-03-17 SU SU762334811A patent/SU668595A3/ru active
- 1976-03-17 CH CH334376A patent/CH622501A5/de not_active IP Right Cessation
- 1976-03-18 IE IE565/76A patent/IE43706B1/en unknown
- 1976-03-18 YU YU00701/76A patent/YU70176A/xx unknown
- 1976-03-18 AU AU12144/76A patent/AU505356B2/en not_active Expired
- 1976-03-18 BE BE165318A patent/BE839746A/xx not_active IP Right Cessation
- 1976-03-18 DD DD191914A patent/DD125686A5/xx unknown
- 1976-03-18 ES ES446188A patent/ES446188A1/es not_active Expired
- 1976-03-19 FR FR7608017A patent/FR2304334A1/fr active Granted
- 1976-03-19 US US05/668,479 patent/US4086361A/en not_active Expired - Lifetime
- 1976-03-19 JP JP51029396A patent/JPS6055505B2/ja not_active Expired
- 1976-11-29 AR AR265659A patent/AR214986A1/es active
-
1977
- 1977-07-06 SU SU772499908A patent/SU645558A3/ru active
- 1977-07-06 SU SU772499557A patent/SU639448A3/ru active
-
1981
- 1981-01-19 CH CH32081A patent/CH628617A5/de not_active IP Right Cessation
- 1981-01-19 CH CH31981A patent/CH630895A5/de not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2610886C2 (sr) | ||
| DE2434911C2 (de) | Phenyläthylamin-Derivate und pharmazeutische Zusammensetzungen | |
| DE1964761B2 (de) | Fluorenon- und Fluorenverbindungen und Arzneimittel, welche diese enthalten | |
| CH622501A5 (sr) | ||
| EP0152868B1 (de) | Isoxazol-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| CH615151A5 (sr) | ||
| CH618438A5 (sr) | ||
| CH650249A5 (de) | Basische oximaether, solche enthaltende pharmazeutische praeparate und verfahren zur herstellung derselben. | |
| CH626056A5 (sr) | ||
| DE2611118C2 (sr) | ||
| DE2610679C2 (de) | Sulfinylgruppenhaltige Oximätherderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel | |
| DE2222931C3 (de) | Piperidinoalkylphenthiazine, Verfahren zur Herstellung derselben sowie diese enthaltende pharmazeutische Mittel | |
| DE1090215B (de) | Verfahren zur Herstellung von Phenthiazinderivaten | |
| CH677669A5 (sr) | ||
| DE2610302A1 (de) | Antidepressive verbindungen | |
| DE1620151C (de) | 10 Piperazino dibenzo eckige Klammer auf a,d eckige Klammer zu cycloheptadien derivate und Verfahren zu ihrer Herstel lung | |
| AT362358B (de) | Verfahren zur herstellung von neuen 6-aryl-2,3, 6,7-tetrahydro-5h-pyrrolo (1,2-a)imidazolen und von deren saeureadditionssalzen | |
| DE1545786A1 (de) | Verfahren zur Herstellung von Carbonsaeure-N-methylpiperaziden | |
| DE3229539A1 (de) | Neue oxamidsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel | |
| DE2454805A1 (de) | Acylderivate | |
| DE1156079B (de) | Verfahren zur Herstellung von 3-Alkylmercaptophenthiazinderivaten | |
| WO1990010628A1 (de) | Neue aryloxy-alkylamine, deren herstellung und diese enthaltende arzneimittel | |
| CH511847A (de) | Verfahren zur Herstellung von neuen serumlipoidvermindernden Pyridinderivaten | |
| DE1274582B (de) | N-substituierte 4-Phenyl-piperidin-4-carbonsaeureaethylesterderivate | |
| CH532030A (de) | Verfahren zur Herstellung von Oximäther |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |